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CARDIOVASCULAR DISEASE
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OBJECTIVES: QoL is increasingly used as a secondary
endpoint to supplement morbidity and mortality data in
clinical trials in CHF for which regulatory bodies such as
EMEA and FDA have drafted guidelines. The aim of the
present study was to compare the draft guidelines and to
discuss their implications.
METHODS: Current guidelines from EMEA and the
FDA were reviewed and analyzed.
RESULTS: The EMEA guidelines require measurement of
12 QoL domains, whereas the FDA proposes the avoidance
of evaluating a wide array of QoL aspects. No guidance is
given with regard to the use of generic or specific question-
naires, or to requirements for psychometric properties. De-
sign issues such as duration of follow-up, or problems re-
lated to patient selection bias due to mortality and loss to
follow-up are not addressed. These differences create diffi-
culties in conducting studies accommodating both Euro-
pean and US agencies. EMEA requirements will result in ex-
actly the problems that the FDA wants to avoid (i.e.,
inclusion of all aspects of QoL in the hope that one or two
domains may be favorably affected by treatment). The rele-
vance of many of the QoL domains to elderly and incapaci-
tated CHF patients (e.g., occupational activities, sexual sat-
isfaction, interpersonal relationships) must be questioned.
CONCLUSION: The draft guidelines incorporating QoL
outcomes are welcomed. However, further and more de-
tailed guidance is required as well as a greater degree of
harmonization between the EMEA and the FDA.
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HYPERTENSION DISEASE MANAGEMENT: A 
RANDOMIZED, COMPARATIVE TRIAL
Borenstein J, Saltiel M, Graber G, Ryu S, Jackson A, 
Weingarten S
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OBJECTIVE: The objective of this study was to compare
two hypertension disease management strategies.
METHODS: Uncontrolled HTN patients were identified
by ICD-9 codes from administrative data and confirmed
by chart review. Patients were randomized to 1) an Alert
group (primary care physician [PCP] and patient notifica-
tion of blood pressure results) or 2) a disease manage-
ment (DM) clinic (pharmacist-PCP co-management). In
consultation PCPs, pharmacists provided DM care utiliz-
ing evidence-based guidelines developed by a multidisci-
plinary team.
RESULTS: At baseline, there were no statistically signifi-
cant differences between groups, including systolic blood
pressure (SBP) and diastolic blood pressure (DBP), demo-
graphics, comorbidities, and anti-hypertensive medica-
tion costs. By intention-to-treat analysis the DM group
had significant reductions in SBP and DBP at 6 and 12
months (SBP/DBP: 22mmHg/9mmHg [n  78] and
22mmHg/4mmHg [n  58], respectively, p  0.01),
compared to baseline. At 18 months, the SBP reduction
was statistically significant (21mmHg [n  31], p 
0.01), but DBP reduction was not (3mmHg). The Alert
group had significant reductions in SBP and DBP at 6,
12, and 18 months (SBP/DBP: 10mmHg/7mmHg
[n  92], 11mmHg/8mmHg [n  81], 11mmHg/
7mmHg [n  39], respectively, p  0.01) compared to
baseline. The reductions in SBP were significantly greater
in the DM group than in the Alert group at 6 and 12
months (22mmHg versus 10mmHg and 22mmHg
versus 11mmHg, p  0.01), but not at 18 months. Dif-
ferences in DBP were not statistically significant. At 12
and 18 months, per-member per-month DM group visit
costs were significantly lower than those of the Alert
group ($12 versus $16, p  0.01; $11 versus $17, p 
0.05, respectively).
CONCLUSIONS: These results suggest that clinically im-
portant BP reductions may be achieved cost-effectively in
a hypertension disease management program.
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COST-EFFECTIVENESS OF THROMBOLYTIC 
AGENTS IN THE TREATMENT OF ACUTE 
MYOCARDIAL INFARCTION
Kamath T, Liu G, Chang K, Cherian J, Feier C, Kerrigan P, 
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OBJECTIVE: The purpose of this study was to evaluate
the cost-effectiveness of tissue plasminogen activator (t-
PA) compared to streptokinase in the treatment of acute
myocardial infarction.
METHODS: The data for this study were obtained from
the GUSTO trial (1972–1992), which is the largest and
the most comprehensive clinical trial studying the two
drugs under investigation, and from other studies that an-
alyzed the data from the GUSTO trial. The GUSTO trial
randomly assigned 41,021 patients around the world to
four different thrombolytic therapies; we focused on the
patients that received t-PA and streptokinase. Inclusion
criteria were requirements of signs and symptoms of myo-
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cardial infarction, chest pain greater than 20 minutes and
irregular specifications of EKG. The outcome measured
was reduction in mortality at a 30-day follow-up. The
study was based on a societal perspective, hence the cost
measure included both direct costs such as cost of hospi-
talizations, drug acquisition, follow-up hospitalizations
and physicians’ fees, and indirect costs. We calculated the
effectiveness measure, using life expectancy, as number of
quality-adjusted life-years (QALYs) saved.
RESULTS: The expected total costs of t-PA treatment
were $16,885 and with streptokinase, the expected total
costs were $14,472. The number of QALYs saved for
each therapy were 12.379 years for t-PA and 12.16 years
for streptokinase. The ICE ratio was calculated to be
$11,171 per QALY.
CONCLUSION: Since the ICE ratio of $11,171/QALY is
less than the most popular cut-off ratio of $40,000/QALY,
we concluded that t-PA is more cost-effective than strep-
tokinase in the treatment of acute myocardial infarctions.
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OBJECTIVE: To examine the costs and outcomes associ-
ated with the use of valsartan, an angiotensin II receptor
blocker, compared to six different anti-hypertensive med-
ications as second-line treatment for mild to moderate
hypertension over 12 months.
METHODS: A decision analytic model was developed to
evaluate the costs and outcomes associated with initiating
treatment with seven different anti-hypertensive medica-
tions. A combination of meta-analysis and predictive logis-
tic regression analysis was used to model effectiveness de-
fined as the proportion of patients responding to anti-
hypertensive treatment (response was defined as a reduction
of diastolic blood pressure to below 90 mmHg or a reduc-
tion of greater than 10 mmHg). The meta-analysis was per-
formed on an intent-to-treat basis. Two regression analyses
were used, one to impute a response rate for those studies
where only change in blood pressure was reported and a
second to determine a dose-response relationship for each
comparator. Costs for drugs, laboratory tests, and physician
visits were obtained from publicly available Ontario
sources. The analysis determined the cost per successful re-
sponder at 12 months for each initial comparator.
RESULTS: The analysis demonstrated that treatment
patterns associated with each medication, particularly
laboratory tests, played an important role in the overall
cost and cost-effectiveness of each therapy as opposed to
simply the drug acquisition cost.
CONCLUSIONS: At least two drugs from each class, an-
giotensin receptor blocker, angiotensin converting en-
zyme inhibitor, and calcium channel blocker, were evalu-
ated and no evidence of class effects was seen.
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DELPHI PANEL SURVEY ON CURRENT 
HYPERTENSION TREATMENT PATTERNS
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OBJECTIVE: Determine current clinical practice in the
treatment of mild-to-moderate uncomplicated hyperten-
sion.
METHODS: Delphi panel survey of general practitioners
and cardiologists in the United States. First round: 11
physician responders. Second round: 10 of 11 physicians
responded. Consensus reached in the second round.
Questions addressed the status quo, JNC-VI guidelines,
initial therapy, and second-line therapy.
RESULTS: Diuretics and ACE inhibitors are more fre-
quently prescribed than other drug classes. HCTZ is the
most frequently used diuretic, atenolol and metoprolol
are the most frequently used beta-blockers. A variety of
drugs are prescribed from ACE inhibitors, calcium chan-
nel blockers and angiotensin-II inhibitors. When a pa-
tient is given combination therapy, the second agent is
typically a diuretic. Physicians generally agreed with the
JNC-VI guidelines, except that: 1) more drugs should be
permissible as first-line therapy (seven physicians regu-
larly consider classes other than diuretics or beta-block-
ers as initial therapy), and 2) comorbidities are a major
factor in drug choice and the guidelines do not ade-
quately address this. Follow-up after initiating drug ther-
apy typically occurs at 1 month. New therapies will gen-
erally be titrated upward once or twice (depending on the
drug) before the drug is discontinued due to lack of effi-
cacy. Once a patient’s hypertension is controlled, moni-
toring occurs every 3 to 4 months. It is extremely rare for
a patient to be unresponsive to all five drug classes. Re-
sults from a series of case studies in which physicians
were asked to select the class of medication they would
prescribe depending on the patient’s age, gender, initial
blood pressure, and initial therapy will be presented.
CONCLUSIONS: This study gives researchers insights
into the differences between clinical practice and clinical
guidelines in hypertension treatment.
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